IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Want to see IDYA full AI Analyst Report?
Top Page
IDEAYA Biosciences
(NASDAQ:IDYA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$34.00
▲(0.27% Upside)
Action:ReiteratedDate:04/10/26
The score is driven primarily by strong balance-sheet positioning but offset by persistent losses and historically weak cash flow. Technicals are currently bearish (below key moving averages with negative MACD), while valuation is constrained by negative earnings and no dividend support. Positive corporate developments provide a modest offset.
Positive Factors
Balance Sheet Strength
Very low historical leverage and roughly $1.02B of equity provide lasting financial flexibility for multi-year clinical development. A strong capital base reduces near-term refinancing risk and supports funding of trials, partnerships, and optionality while programs de-risk.
Negative Factors
Persistent Losses
Large, ongoing operating losses and a ~-52% net margin in 2025 show the business is not yet generating profits. Continued negative returns reduce internal funding capacity, pressure capital deployment decisions, and mean outcomes depend on clinical success or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low historical leverage and roughly $1.02B of equity provide lasting financial flexibility for multi-year clinical development. A strong capital base reduces near-term refinancing risk and supports funding of trials, partnerships, and optionality while programs de-risk.
Read all positive factors
IDEAYA Biosciences (IDYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.54B
Dividend YieldN/A
Average Volume (3M)1.44M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth3024.43%
EPS Growth61.00%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding87,814,026
10 Day Avg. Volume2,545,933
30 Day Avg. Volume1,443,455
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit11.58
Enterprise Value/Ebitda-20.60
Forecast
1Y Price Target
$56.25Price Target Upside65.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.97
Revenue Forecast (FY)$34.79M
IDEAYA Biosciences Business Overview & Revenue Model
Company Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product...
How the Company Makes Money
null...
IDEAYA Biosciences Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M |
| Gross Profit | 214.12M | 3.17M | 19.38M | 48.83M | 26.22M |
| EBITDA | -154.72M | -270.64M | -108.95M | -56.55M | -48.04M |
| Net Income | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M |
Balance Sheet | |||||
| Total Assets | 1.11B | 1.12B | 649.32M | 387.97M | 381.35M |
| Cash, Cash Equivalents and Short-Term Investments | 639.39M | 676.32M | 525.11M | 364.83M | 246.77M |
| Total Debt | 27.91M | 19.17M | 2.87M | 3.48M | 5.18M |
| Total Liabilities | 86.39M | 64.94M | 28.23M | 38.51M | 79.83M |
| Stockholders Equity | 1.02B | 1.06B | 621.09M | 349.45M | 301.51M |
Cash Flow | |||||
| Free Cash Flow | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M |
| Operating Cash Flow | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M |
| Investing Cash Flow | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M |
| Financing Cash Flow | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M |
IDEAYA Biosciences Technical Analysis
Positive
33.91
Price Trends
32.42
Positive
33.65
Positive
29.99
Positive
Market Momentum
-0.04
Negative
57.45
Neutral
33.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 33.91 is above the 20-day moving average (MA) of 31.92, above the 50-day MA of 32.42, and above the 200-day MA of 29.99, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 57.45 is Neutral, neither overbought nor oversold. The STOCH value of 33.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.
IDEAYA Biosciences Risk Analysis
IDEAYA Biosciences disclosed 76 risk factors in its most recent earnings report. IDEAYA Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IDEAYA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $7.01B | -25.70 | -203.17% | ― | ― | -34.71% | |
63 Neutral | $2.94B | 53.53 | -10.26% | ― | 91.34% | 88.80% | |
62 Neutral | $4.15B | -18.39 | -79.16% | ― | 110.46% | 86.22% | |
58 Neutral | $3.09B | 2.92 | -7.31% | ― | 120.01% | 78.83% | |
52 Neutral | $2.54B | -9.19 | -11.10% | ― | 3024.43% | 61.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.64B | -5.02 | -34.11% | ― | 78.34% | -161.91% |
* Healthcare Sector Average
IDYA
IDEAYA Biosciences
28.90
11.15
62.82%
AGIO
Agios Pharma
27.56
-0.76
-2.68%
TVTX
Travere Therapeutics
44.91
24.96
125.11%
CELC
Celcuity
144.98
134.86
1332.61%
ARQT
Arcutis Biotherapeutics
23.49
9.17
64.04%
BEAM
Beam Therapeutics
30.08
14.09
88.12%
IDEAYA Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial
Positive
Apr 9, 2026
On April 8, 2026, IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDE849, its investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.